Literature DB >> 31839483

The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer.

ZhiQuan Xiang1, Raj K Kurupati1, Yan Li1, Klaudia Kuranda2, Xiangyang Zhou1, Federico Mingozzi2, Katherine A High2, Hildegund C J Ertl3.   

Abstract

Transfer of genes by adeno-associated virus (AAV) vectors is benefiting patients with particular genetic defects. Challenges remain by rejection of AAV-transduced cells, which may be caused by CD8+ T lymphocytes directed to AAV capsid antigens. Reducing the number of CpG motifs from the genome of AAV vectors reduces expansion of naive T cells directed against an epitope within the capsid. In contrast, AAV capsid-specific memory CD8+ T cells respond more vigorously to AAV vectors lacking CpG motifs than to those with CpG motifs presumably reflecting dampening of T cell expansion by cytokines from the innate immune system. Depending on the purification method, AAV vector preparations can contain substantial amounts of empty AAV particles that failed to package the genome. Others have used empty particles as decoys to AAV-neutralizing antibodies. We tested if empty AAV vectors given alone or mixed with genome-containing AAV vectors induce proliferation of naive or memory CD8+ T cells directed to an antigen within an AAV capsid. Naive CD8+ T cells failed to respond to empty AAV vectors, which in contrast induced expansion of AAV-specific memory CD8+ T cells.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV gene transfer; CpG motifs; T cell response; memory T cell response; mouse model; primary T cell response

Mesh:

Substances:

Year:  2019        PMID: 31839483      PMCID: PMC7054717          DOI: 10.1016/j.ymthe.2019.11.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  39 in total

1.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

2.  CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.

Authors:  Te-Lang Wu; Hua Li; Susan M Faust; Emily Chi; Shangzhen Zhou; Fraser Wright; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2013-09-30       Impact factor: 11.454

3.  Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates.

Authors:  Hua Li; Marcio O Lasaro; Bei Jia; Shih Wen Lin; Larissa H Haut; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

4.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

5.  CpG-depleted adeno-associated virus vectors evade immune detection.

Authors:  Susan M Faust; Peter Bell; Benjamin J Cutler; Scott N Ashley; Yanqing Zhu; Joseph E Rabinowitz; James M Wilson
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

6.  Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Authors:  Sylvie Boutin; Virginie Monteilhet; Philippe Veron; Christian Leborgne; Olivier Benveniste; Marie Françoise Montus; Carole Masurier
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

7.  A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.

Authors:  Jianping Lin; Roberto Calcedo; Luk H Vandenberghe; Peter Bell; Suryanarayan Somanathan; James M Wilson
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

8.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

9.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

Authors:  Jean Bennett; Jennifer Wellman; Kathleen A Marshall; Sarah McCague; Manzar Ashtari; Julie DiStefano-Pappas; Okan U Elci; Daniel C Chung; Junwei Sun; J Fraser Wright; Dominique R Cross; Puya Aravand; Laura L Cyckowski; Jeannette L Bennicelli; Federico Mingozzi; Alberto Auricchio; Eric A Pierce; Jason Ruggiero; Bart P Leroy; Francesca Simonelli; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2016-06-30       Impact factor: 79.321

10.  Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.

Authors:  Valerie Ferreira; Harald Petry; Florence Salmon
Journal:  Front Immunol       Date:  2014-03-03       Impact factor: 7.561

View more
  16 in total

Review 1.  Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll.

Authors:  J Fraser Wright
Journal:  Mol Ther       Date:  2020-07-14       Impact factor: 11.454

2.  Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?

Authors:  J Fraser Wright
Journal:  Mol Ther       Date:  2020-02-08       Impact factor: 11.454

3.  Human and Insect Cell-Produced Recombinant Adeno-Associated Viruses Show Differences in Genome Heterogeneity.

Authors:  Ngoc Tam Tran; Emilie Lecomte; Sylvie Saleun; Suk Namkung; Cécile Robin; Kristina Weber; Eric Devine; Veronique Blouin; Oumeya Adjali; Eduard Ayuso; Guangping Gao; Magalie Penaud-Budloo; Phillip W L Tai
Journal:  Hum Gene Ther       Date:  2022-04       Impact factor: 4.793

4.  Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.

Authors:  Maria A Parker; Laura R Erker; Isabelle Audo; Dongseok Choi; Saddek Mohand-Said; Kastytis Sestakauskas; Patrick Benoit; Terence Appelqvist; Melissa Krahmer; Caroline Ségaut-Prévost; Brandon J Lujan; Ambar Faridi; Elvira N Chegarnov; Peter N Steinkamp; Cristy Ku; Mariana Matioli da Palma; Pierre-Olivier Barale; Sarah Ayelo-Scheer; Andreas Lauer; Tim Stout; David J Wilson; Richard G Weleber; Mark E Pennesi; José Alain Sahel; Paul Yang
Journal:  Am J Ophthalmol       Date:  2022-03-04       Impact factor: 5.488

Review 5.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

6.  Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes.

Authors:  Bradley A Hamilton; J Fraser Wright
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

Review 7.  New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.

Authors:  Maja van Hees; Sofie Slott; Anders Højgaard Hansen; Heon Seok Kim; Hanlee P Ji; Kira Astakhova
Journal:  Mol Ther       Date:  2021-06-04       Impact factor: 11.454

Review 8.  Human Immune Responses to Adeno-Associated Virus (AAV) Vectors.

Authors:  Giuseppe Ronzitti; David-Alexandre Gross; Federico Mingozzi
Journal:  Front Immunol       Date:  2020-04-17       Impact factor: 7.561

Review 9.  Immune Responses to Viral Gene Therapy Vectors.

Authors:  Jamie L Shirley; Ype P de Jong; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

10.  Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy.

Authors:  Thais B Bertolini; Jamie L Shirley; Irene Zolotukhin; Xin Li; Tsuneyasu Kaisho; Weidong Xiao; Sandeep R P Kumar; Roland W Herzog
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.